The impact of heterogeneous interlesional tumor response on outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) remains unclear. We aimed to evaluate the role of prostate ...

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. After the use of liver-directed therapies, it is challenging to differentiate between nonviable tumor and ...

Evaluation of Mitochondrial Complex 1 Density with [18 F]BCPP-EF in a Murine Model and Individuals with Friedreich Ataxia ...

The variable response to cancer immunotherapies highlights a critical gap in our ability to predict and monitor treatment efficacy. To address this, there is an urgent clinical need for advanced ...

This soft-cover booklet is a completely revised English edition published only 2 y after the first English edition. The initial edition was met with great approval by the English-speaking world, ...

Glypican-3 is a proteoglycan that is overexpressed on the surface of hepatocellular carcinoma (HCC) cells ([1][1],[2][2]). Recently, [68Ga]Ga-RAYZ-8009 was introduced as a promising PET tracer for HCC ...

Prostate cancer (PCa) is a leading cause of cancer deaths, making effective early detection, precise staging, and monitoring of biochemical recurrence crucial. Next-generation prostate-specific ...

There is a pressing need for improved standardization of terminology and data in nuclear medicine. The field is experiencing unprecedented growth, driven by advances in radiopharmaceutical therapy ...

We report the synthesis and evaluation of the first 3,6,10,13-tetraaza-1,8 (2,6)-dipyridinacyclotetradecaphane-3,6,10,13-tetraacetic acid (PYTA) bifunctional chelators (BFCs) for 225Ac coordination.

The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is currently being investigated as a potential therapeutic target in several ...

Cure rates are excellent in classical Hodgkin lymphoma. The challenge is tailoring the treatment to the individual patient to avoid not only overtreatment and treatment-related sequelae but also ...

Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals ...